Lung cancer in never smokers: how can we identify those at highest risk?

DAY 2

Chaired by: Professor Mat Callister (Leeds) and Dr Tanya Patrick (London)

9:00am	Integrating epidemiologic, genomic, and experimental data to outline a unifying framework for lung adenocarcinoma in never smokers Dr Maria Theresa Landi (USA)
9:30am	Understanding and integrating environmental and inherited risk Dr Frank McCaughan (Cambridge)
10:00am	How do we identify high risk people? Biomarkers, risk profiling and screening Dr Hillary Robbins (Lyon)

9:00 AM

90 MINUTE SESSION

Learning objectives

To understand the key genetic drivers of lung cancer in never-smokers, understand how these differ from smoking-related disease, and recognise the clinical implications for diagnosis and treatment pathways.
To describe the distinctive features of the tumour micro-environment in lung cancer in never-smokers, including inflammatory pathways and immune cell interactions, and understand their implications for tumour development, progression and treatment.
To understand current and emerging approaches to risk stratification in never-smokers, including the role of biomarkers and risk prediction models, with reference to the principles of screening, balancing benefit against harm and maximising mortality benefit.